Driving scientific progress through Research Use Only (RUO) products
Providing early access to innovative biomarkers to enhance diagnostic research
To manage today’s complex healthcare landscape and prepare for growing expectations for diagnostic testing, there is an urgent need for continuous innovation in diagnostics. However, a launched IVD assay can take years to become a standard of care, even with strong evidence of its benefits.
Our ‘Research Use Only’ (RUO) products portfolio delivers advanced, reliable tools and early access to cutting-edge technology, empowering researchers to explore the best possible future diagnostic solutions. By equipping scientists with innovative biomarkers now, we allow them to understand the benefits and potential use cases of new biomarkers earlier, enabling them to better understand disease biology, prepare laboratories in advance, and pave the way for upcoming IVD approvals leading to advanced healthcare practices.
Enabling better understanding of disease biology in high medical value areas
At Roche, as a leader in in vitro diagnostics, we are deeply committed to sustained innovation, as demonstrated by our industry-leading R&D investment. Research Use Only (RUO) products accelerate evidence generation and market acceptance of biomarkers not linked to a specific intended use.
Therefore, a key area of our investment is in the development of research use only medical devices to gain a better understanding of disease biology in critical high medical value areas such as:
- Neurology
- Oncology
- Infectious diseases (ID)
- Immunology
- Cardiovascular disease
By addressing the unmet needs of today's patients, we are equipping scientists with the tools to explore innovative solutions, enhance disease understanding, and refine treatment guidelines, ultimately improving patient care
Empowering researchers to shape tomorrow’s diagnostics
Through RUO products, we ensure Roche stays at the forefront of research and enables scientists to gain insights into critical high-medical-value areas. We are committed to identifying additional biomarkers to advance scientific knowledge in areas like cardiac diseases and on MassSpec.
By enabling today's research, our RUO products are paving the way for improved patient outcomes and advanced healthcare practices tomorrow.
Featured products
Benefits of Core Lab Research Solutions from Roche
Gain early access to cutting-edge biomarkers
Roche’s RUO products portfolio delivers advanced, reliable tools and early access to cutting-edge technology that empower you to confidently drive critical breakthroughs and shape tomorrow’s diagnostics.
Our most developed area is neurology, where we provide a comprehensive panel for neurodegeneration research. We are committed to extending our research portfolio beyond neurology and are actively working towards powerful RUO products for vital research in oncology, cardiometabolic conditions, women’s health, and immunology.
This expanding portfolio is the tangible result of our early access strategy. By making these diverse and innovative biomarkers available for your research now, we empower you to accelerate discovery and generate new insights, often years before a potential fully-validated IVD might become available.
Accelerate disease understanding with innovative assays
We are committed to further building our RUO products portfolio to support research and advance scientific knowledge across multiple critical disease areas, including oncology, cardiometabolic conditions, women’s health, and immunology. Some of the innovative biomarkers we are exploring for the future include:
- Amyloid beta 40 (Aß40)*
- Brain-derived tau (BD-tau)*
- ETS-specific gene (ERG)*
- Pro-surfactant protein B (Pro-SPB)*
- Synaptosomal Associated Protein 25 (SNAP-25)*
Roche is not just a provider of laboratory research products such as advanced assays, but a dedicated partner. When a promising biomarker gains attention in the scientific community, we can offer it as an RUO, enabling you to harness these innovations and translate them into impactful scientific progress.
Perform RUO research on your existing Roche platforms
The Elecsys® RUO assays utilize electrochemiluminescence immunoassay (ECLIA) technology. They can be seamlessly integrated into your lab utilizing Roche’s automated cobas® e 801 and cobas® e 402 immunoassay analyzers.
*Product is in development and not commercially available.
Product availability may vary from country to country.